Stay updated on Nivolumab With Azacitidine in AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab With Azacitidine in AML Clinical Trial page.

Latest updates to the Nivolumab With Azacitidine in AML Clinical Trial page
- Check6 days agoChange DetectedThe page now lists the updated protocol revision v3.5.3, replacing the previous v3.5.2. This indicates a new version of the study protocol document.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the page metadata.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check56 days agoChange DetectedThe site revision has been updated to v3.4.3. The previous revision v3.4.2 has been removed.SummaryDifference0.0%

- Check85 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing the older site-wide funding/status notice. No study content, eligibility criteria, or outcome measures were altered.SummaryDifference0.3%

- Check92 days agoChange DetectedNotice explains that due to a lapse in government funding, information on this site may not be up to date and that the NIH Clinical Center is open, with updates at cc.nih.gov and opm.gov. The site revision was updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nivolumab With Azacitidine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab With Azacitidine in AML Clinical Trial page.